Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV

We report the safety and tolerability of 87 infusions of lentiviral vector–modified autologous CD4 T cells (VRX496-T; trade name, Lexgenleucel-T) in 17 HIV patients with well-controlled viremia. Antiviral effects were studied during analytic treatment interruption in a subset of 13 patients. VRX496-...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Tebas, Pablo, Stein, David, Binder-Scholl, Gwendolyn, Mukherjee, Rithun, Brady, Troy, Rebello, Tessio, Humeau, Laurent, Kalos, Michael, Papasavvas, Emmanouil, Montaner, Luis J., Schullery, Daniel, Shaheen, Farida, Brennan, Andrea L., Zheng, Zhaohui, Cotte, Julio, Slepushkin, Vladimir, Veloso, Elizabeth, Mackley, Adonna, Hwang, Wei-Ting, Aberra, Faten, Zhan, Jenny, Boyer, Jean, Collman, Ronald G., Bushman, Frederic D., Levine, Bruce L., June, Carl H.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2013
נושאים:
Gene Therapy
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3587318/
https://ncbi.nlm.nih.gov/pubmed/23264589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-07-447250
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים